These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33496858)

  • 1. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
    Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
    Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
    C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
    Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
    Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
    Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
    Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
    Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
    Golabi P; Owrangi S; Younossi ZM
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.
    Allen AM; Van Houten HK; Sangaralingham LR; Talwalkar JA; McCoy RG
    Hepatology; 2018 Dec; 68(6):2230-2238. PubMed ID: 29774589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
    Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
    Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database.
    Boursier J; Shreay S; Fabron C; Torreton E; Fraysse J
    EClinicalMedicine; 2020 Aug; 25():100445. PubMed ID: 32775971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data.
    Fishman J; Tapper EB; Dodge S; Miller K; Lewandowski D; Bogdanov A; Bonafede M
    Curr Med Res Opin; 2023 Nov; 39(11):1425-1429. PubMed ID: 37740457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
    Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
    J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
    Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
    Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.